drugset / Trial / NCT06064903
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LL).
Timeline
- Start
- 2024-04-21
- Primary completion
- 2028-09-30
- Completion
- 2040-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7-CART01 | Cell therapy | 250000 cells/kg | Intravenous |
| Subject | CD7-CART01 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | CD7-CART01 | Cell therapy | 1e+06 cells/kg | Intravenous |